Cadrenal’s CAD-1005 Shows >25% Reduction in HIT Thrombotic Events — Cadrenal Therapeutics, Inc.

Event summary

Cadrenal Therapeutics presented late-breaking Phase 2 data for CAD-1005 at ISTH 2026, showing >25% reduction in thrombotic events in HIT patients.
The trial was the first randomized, blinded, placebo-controlled study for Heparin-Induced Thrombocytopenia (HIT).
CAD-1005 demonstrated no serious adverse events attributable to the drug and no major bleeding in SRA+ patients.
The company plans to advance CAD-1005 into Phase 3 trials, with Orphan Drug and Fast Track designations from FDA and EMA.

The big picture

Cadrenal’s data suggests a paradigm shift in HIT treatment, targeting the root cause of immune-mediated platelet activation rather than just reducing thrombin generation. The $2 billion peak revenue opportunity highlights the unmet need in this life-threatening condition. Success could position Cadrenal as a key player in rare immunothrombotic disorders.

What we're watching

Clinical Validation: Whether CAD-1005 can sustain its efficacy signal in the larger Phase 3 trial.
Regulatory Pathway: The pace at which FDA and EMA will review CAD-1005 given its Orphan Drug and Fast Track designations.
Commercialization Strategy: How Cadrenal positions CAD-1005 for potential partnerships or standalone commercialization.